Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed for depression and anxiety yet are associated with an increased bleeding risk. While this risk is mainly linked to the decrease in platelet serotonin content, thus abnormal platelet functions, some studies suggest an inherent effect of SSRIs on coagulation. Hence, we performed a literature review to provide an overview of the different studies assessing SSRI's effects on coagulation assays routinely used in clinical practice. A search of the PubMed database yielded 22 relevant studies. Results were inconsistent: While some studies showed minor changes in routine coagulation assays, namely, prothrombin time and activated partial thromboplastin time, the majority found no significant effects of SSRIs on coagulation tests. Then, we specifically investigated the impact of citalopram, a commonly prescribed SSRI, on the thrombin generation assay (TGA) allowing the detection of any potential procoagulant or anticoagulant effect. TGA was performed in platelet‐poor plasma from 14 healthy volunteers spiked with citalopram at therapeutic (0.1 and 0.5 μM) and supratherapeutic (50 μM) concentrations. TGA parameters were not significantly changed compared to the control condition regardless of the citalopram concentration. All in all, our findings failed to demonstrate any compromised coagulation function associated with SSRI therapy.
2 September 2026 in International Journal of Laboratory Hematology
Introduction: It is recommended to detect lupus anticoagulant (LA) using two phospholipid‐dependent clotting assays, including a LA‐sensitive activated partial‐thromboplastin‐time (aPTT). Among these reagents, Staclot‐LA assay is performed on a mixture of test and normal plasma with and without hexagonal phase phospholipids. However, its lack of validation on automated coagulation analyser is a major drawback. We aimed i/to assess the analytical performance of Staclot‐LA assay on automated system; ii/to compare inter‐laboratory agreement of Staclot‐LA performed on semi‐automated or fully automated analysers using two external‐quality‐assurance (EQA) programs data. Methods: We adapted the Staclot‐LA assay (Stago) set‐up on a STA‐R‐Max analyser and locally validated the manufacturer's recommended cut‐off for positive LA testing using samples from healthy volunteers. Reproducibility and accuracy were assessed using internal quality controls (IQC, Staclot‐LA1/LA2) over a five‐year period. Staclot‐LA results from EQA Probioqual and ECAT were compared between semi‐ and fully‐automated analysers. Results: Agreement of our LA results (positive or negative) was observed in 100% of IQC ( n = 130) and EQA ( n = 58) samples. Probioqual and ECAT interlaboratory Staclot‐LA results showed full agreement for 96.2% and 89.7% in semi‐automated system users vs 96.7% and 92.5% in automated system users. The system had no significant impact on the qualitative results (Probioqual p = 1.000; ECAT p = 0.5912), even though we observed increasing biases of the differences in clotting times, especially in LA positive samples on automated vs semi‐automated analysers. Conclusion: Staclot‐LA assay can be reliably performed on a fully automated system, thus paving the way for wider accessibility and widespread use.